1Fotopoulou C, Savatis K.Primary radical surgery in elderly patient's with epithelial ovarian cancer analysis of surgical outcome and long-term survival [J].lnt J Gynecol Cancer, 2010,20 ( 1 ) : 34-40.
2Tracey EA,Roder DM. Reasons for improved survival from ovarian can- cer in New South Wales, Australia, Between 1980 and 2003: Implica- tions for Cancer Control[J]. Gynecol Cancer, 2009,19(4):591-599.
3Chang SJ, Bristov RE, Ryu HS. Impact of complete cytoreduction leav- ing no gross residual disease associated with radical cytoreduetive surgi- cal procedures on survival in advanced ovarian cancer [J].Ann Surg On- col, 2012 (19) :4059--4067.
4Britow RE,Tomacruz RS.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis[J].J Clin Oncol, 2002,20(5):1248-1259.
5Du Bois A, Reuss A.Role of surgical outcome as prognostic factor in ad- vanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsge- meinscbaft Gynaekologische Onkologie Studiengruppe Ovarialkarziuom (AGO-OVAR) and the Gmupe d'Investigateurs Nationaux Pour les E- tudes des Cancers de l'Ovaire(GINECO)[J].Cancer,2009,115:1234-1244.
6Polterauer S,Vergote I, Concin N,et al.Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIa-IV: anal- ysis of the OVCAD data[J].Gynecol Cancer, 2012,22:380-385.
7Griffiths CT,Fuller AF.Intensive surgical and chemotherapcutic manage- ment of advanced ovarian cancer [J]. Surg Clin North Am,1978,58(1): 131-142.
8Hegazy MA, Hegazl RA,Elshafei MA,et al. Neoadjuvantchemotherapy versus primary surgery in advanced ovarian carcinomia[J].World Journal of Surgical Oncology,2005,3(1): 57-64.
9Pectasides D, Farmakis D,KoumarianouA.The Role of Neoadjuvant Chemotherapy in the Treatment of Advanced Ovarian Cancer[J]. Oncolo- gy, 2005,68:64-70.
10Vergote I, Trap6 CG, Amant F,et al.Neoadjuvant chemotherapy or pri- mary surgery in stage IIIc-IV ovarian cancer [J].New Engl Med, 2010,363:943-953.
3Rustin GJ,Quinn M,Thigpen T,et al.New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)[J].J Natl Cancer Inst,2004,96:487-488.
4Bristow RE,Tomacruz RS,Armstrong DK,et al.Survival effect of maximal cyto-reductive surgery for advanced ovarian carcinoma during the platinum era:ametaan-alysis[J].J Clin Oncol,2002,20 (5):1248-1259.
5Griffiths CT,Fuller AF.Intensive surgical and chemotherapcutic management of advanced ovarian cancer[J].Surg Clin North Am,1978,58(1):131-142.
6Hegazy MA,Hegazi RA,Elshafei MA,et al.Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma[J].World J Surg Oncol,2005,31(3):57-65.
9Weinberg LE,Rodriguez G,Hurteau JA.The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer[J].J Surg Oncol,2010;101(4):334-43.
10Mc Lean KA,Shah CA,Thompson SA,et al.Ovarian cancer in the elderly:outcomes with neoadjuvant chemotherapy or primary cytoreduction[J].Gynecol Oncol,2010;118(1):43-6.
